Nephrotect (Acetylcysteine, Glycine, L-Lysine Acetate, L-Tryptophan, Glycyl-Tyrosine, L-Arginine, L-Histidine, L)

The acetylcysteine component provides cysteine, a key precursor for glutathione, the body’s primary intracellular antioxidant. The additional amino acids (glycine, lysine acetate, tryptophan, glycyl‑tyrosine, arginine, histidine) support nitric‑oxide production, protein synthesis, and cellular repair pathways, collectively enhancing antioxidant capacity and renal blood flow.

The dose of Nephrotect is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment setting. Healthcare professionals set the appropriate infusion volume and rate according to established clinical protocols.

Safety data for Nephrotect in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Compared with single‑ingredient agents such as plain acetylcysteine, Nephrotect offers a broader amino‑acid profile that targets multiple metabolic pathways, potentially providing more comprehensive antioxidant and vasodilatory effects. However, clinical choice depends on specific patient needs, existing protocols, and physician judgment.

Nephrotect must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Nephrotect is given intravenously. The solution is diluted according to the prescribing information and infused over a period defined by the treating clinician, typically using a controlled infusion pump to ensure a steady rate and minimize infusion‑related reactions.

Serious risks include anaphylactoid reactions such as rash, bronchospasm, or angioedema, severe hypotension during rapid infusion, and rare cases of hemolysis in patients with glucose‑6‑phosphate dehydrogenase deficiency. Prompt recognition and medical management are essential if these events occur.

Nephrotect should be avoided in patients with known hypersensitivity to any of its components, those with confirmed G6PD deficiency due to hemolysis risk, and individuals who cannot tolerate intravenous infusions. Clinicians should also exercise caution in patients receiving multiple vasodilators or high‑dose antioxidant therapies.